Our Anti-Dopamine Transporter, C-Terminus rabbit polyclonal primary antibody from PhosphoSolutions is produced in-house. It detects human, mouse, non-human primate, and rat Dopamine Transporter, C-Terminus and is antigen affinity purified from pooled serum. It is great for use in WB, IHC.
Western blot of human striatal lysate showing specific immunolabeling of the ~88 kDa DAT protein.
The dopamine transporter (DAT) is responsible for the reaccumulation of dopamine after it has been released. DAT antibodies and antibodies for other markers of catecholamine biosynthesis are widely used as markers for dopaminergic and noradrenergic neurons in a variety of applications including depression, schizophrenia, Parkinson’s disease and drug abuse (Kish et al., 2001; Zhu et al., 2000; Zhu et al., 1999). Levels of DAT protein expression are altered by chronic drug administration (Wilson et al., 1996).
Antigen Affinity Purified from Pooled Serum
Polyclonal
IgG
IHC, WB
Rabbit
SLC6A3
80 kDa
Synthetic peptide corresponding to amino acid residues from the intracellular C-terminal region of human dopamine transporter, conjugated to keyhole limpet hemocyanin (KLH).
Human, Mouse, Non-Human Primate, Rat
AB_2492076
Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.
Liquid
Prepared from pooled rabbit serum by affinity purification using a column matrix to which the peptide immunogen was coupled.
10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol.
WB: 1:1000
WB Brain: 1:1000
IHC: 1:100-1:1000
Unconjugated
Specific for endogenous levels of the ~80 kDa DAT protein. Diffuse band may be observed between ~70-85 kDa due to variable glycosylation.
Western blots performed on each lot.
For research use only. Not intended for therapeutic or diagnostic use. Use of all products is subject to our terms and conditions, which can be viewed on our website.
After date of receipt, stable for at least 1 year at -20°C.
Blue Ice
DA transporter antibody, DAT 1 antibody, DAT antibody, DAT1 antibody, Dopamine transporter 1 antibody, Dopamine transporter antibody, PKDYS antibody, SC6A3_HUMAN antibody, SLC6A3 antibody, Sodium dependent dopamine transporter antibody, Sodium-dependent dopamine transporter antibody, Solute carrier family 6 (neurotransmitter transporter dopamine) member 3 antibody, Solute carrier family 6 (neurotransmitter transporter) member 3 antibody, Solute carrier family 6 member 3 antibody, Variable number tandem repeat (VNTR) antibody
Cuevas, E., et al. 2020. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson’s disease. Nutritional Neuroscience, Dec. 21, pp.1-18.
Lloyd, J.T., et al. 2022. Dopamine Dysregulation and Altered Responses to Drugs Affecting Dopaminergic Transmission in a New Dopamine Transporter Knockout (DAT-KO) Rat Model. Neuroscience, 491, pp.43-64.
Sarkar, S., et al. 2015. Histopathological and electrophysiological indices of rotenone-evoked dopaminergic toxicity: Neuroprotective effects of acetyl-l-carnitine. Neuroscience Letters, 606, pp.53-59.
Rosas-Hernandez, H., et al. 2019. Stretch-Induced Deformation as a Model to Study Dopaminergic Dysfunction in Traumatic Brain Injury. Neurochemical Research, 44(11), pp.2546-2555.
Haycock, J.W., et al. 2003. Marked disparity between age‐related changes in dopamine and other presynaptic dopaminergic markers in human striatum. Journal of Neurochemistry, 87(3), pp.574-585.
Lloyd, J.T., et al. 2022. Dopamine Dysregulation and Altered Responses to Drugs Affecting Dopaminergic Transmission in a New Dopamine Transporter Knockout (DAT-KO) Rat Model. Neuroscience, 491, pp.43-64.
Bulk Order Anti-Dopamine Transporter, C-Terminus Antibody